PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC
The biomarker analysis of patients enrolled on part B of the CheckMate 914 trial explored the effects of PD-L1 and KIM-1 expression.
Related Articles
Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors
Preclinical data suggest that DLL3-TOPAbody has antitumor activity and could provide a survival advantage in DLL3-expressing tumor cells, including SCLC.
100 hospitals and health systems with great oncology programs | 2024
Becker’s is proud to announce its 2024 list of hospitals and health systems recognized for excellence in oncology.
Targeting DLK1 in neuroblastoma
An ideal cell surface target has ubiquitously high cancer expression, absence from healthy tissues, and an essential role cancer initiation and/or maintenance. In this issue…
Tell Congress to reduce cancer treatment costs for patients
Big hospital systems are exploiting a Medicare loophole to charge older cancer patients thousands of dollars more per year for cancer treatment. Tell your members…
Mobile ‘Man Van’ spots prostate cancer more quickly and cheaply than
Mobile testing ‘Man Van’ can diagnose prostate cancer in at-risk groups earlier and more affordably than GPs, according to new research.
HRD Testing in Advanced Ovarian Cancer
In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’ re speaking with…
Goal-focused Therapy Reduced Distress in Latino Testicular Cancer Survivors – Oncology Nurse Advisor
Postintervention and 3-month follow-up assessments were evaluated to determine the feasibility and effectiveness of GET in managing distress in young Latino men with testicular cancer.
Fox Chase Cancer Center’s Dr. Vanessa Wookey Presents Rectal Cancer Research at 24th Annual ECOG-ACRIN Young Investigator Symposium
PHILADELPHIA (November 12, 2024) — For patients with cancer in the lower part of the rectum that has not spread to the lymph nodes, chemotherapy…
Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MS
Dr Thaker discusses the rationale for combining relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer, and the future of the ROSELLA trial.
BMT Oncologist in Beautiful Northern California: State-of-the-Art Facility & High Earning Potential at Sutter Health
Sutter Medical Group (SMG) seeks to hire a BE/BC Bone Marrow Transplant Oncologist to join their dynamic team in Sacramento, CA. High income potential, (salary…
